<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26798851</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>03</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1699-3993</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>51</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2015</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drugs of today (Barcelona, Spain : 1998)</Title>
          <ISOAbbreviation>Drugs Today (Barc)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Triazole antifungals: a review.</ArticleTitle>
        <Pagination>
          <StartPage>705</StartPage>
          <EndPage>718</EndPage>
          <MedlinePgn>705-18</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1358/dot.2015.51.12.2421058</ELocationID>
        <Abstract>
          <AbstractText>Invasive fungal infections and systemic mycosis, whether from nosocomial infection or immunodeficiency, have been on an upward trend for numerous years. Despite advancements in antifungal medication, treatment in certain patients can still be difficult for reasons such as impaired organ function, limited administration routes or poor safety profiles of the available antifungal medications. The growing number of invasive fungal species becoming resistant to current antifungal medications is of appreciable concern. Triazole compounds containing one or more 1,2,4-triazole rings have been shown to contain some of the most potent antifungal properties. Itracon-azole and fluconazole were some of the first triazoles synthesized, but had limitations associated with their use. Second-generation triazoles such as voriconazole, posa-conazole, albaconazole, efinaconazole, ravuconazole and isavuconazole are all derivatives of either itraconazole or fluconazole, and designed to overcome the deficiencies of their parent drugs. The goal of this manuscript is to review antifungal agents derived from triazole.</AbstractText>
          <CopyrightInformation>Copyright 2015 Prous Science, S.A.U. or its licensors. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Peyton</LastName>
            <ForeName>L R</ForeName>
            <Initials>LR</Initials>
            <AffiliationInfo>
              <Affiliation>University of Arizona and Pima College, Tucson, Arizona, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gallagher</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>University of Arizona and Pima College, Tucson, Arizona, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hashemzadeh</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>University of Arizona and Pima College, Tucson, Arizona, USA. mhashemz1@yahoo.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Spain</Country>
        <MedlineTA>Drugs Today (Barc)</MedlineTA>
        <NlmUniqueID>101160518</NlmUniqueID>
        <ISSNLinking>1699-3993</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D058888">14-alpha Demethylase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000935">Antifungal Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014230">Triazoles</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D058888" MajorTopicYN="N">14-alpha Demethylase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000935" MajorTopicYN="N">Antifungal Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009181" MajorTopicYN="N">Mycoses</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014230" MajorTopicYN="N">Triazoles</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Albaconazole</Keyword>
        <Keyword MajorTopicYN="N">Azole</Keyword>
        <Keyword MajorTopicYN="N">CYP51</Keyword>
        <Keyword MajorTopicYN="N">Cytochrome P450</Keyword>
        <Keyword MajorTopicYN="N">Efinaconazole</Keyword>
        <Keyword MajorTopicYN="N">Fluconazole</Keyword>
        <Keyword MajorTopicYN="N">Invasive fungal infection</Keyword>
        <Keyword MajorTopicYN="N">Isavuconazole</Keyword>
        <Keyword MajorTopicYN="N">Isavuconazonium sulfate</Keyword>
        <Keyword MajorTopicYN="N">Itraconazole</Keyword>
        <Keyword MajorTopicYN="N">Lanosterol 14Î±-demethylase</Keyword>
        <Keyword MajorTopicYN="N">Posaconazole</Keyword>
        <Keyword MajorTopicYN="N">Ravuconazole</Keyword>
        <Keyword MajorTopicYN="N">Triazole</Keyword>
        <Keyword MajorTopicYN="N">Voriconazole</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>1</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>1</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>3</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26798851</ArticleId>
        <ArticleId IdType="doi">10.1358/dot.2015.51.12.2421058</ArticleId>
        <ArticleId IdType="pii">2421058</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
